

Alberto Esquenazi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7515252/publications.pdf>

Version: 2024-02-01

67
papers

3,578
citations

159585

30
h-index

144013

57
g-index

77
all docs

77
docs citations

77
times ranked

3318
citing authors

#	ARTICLE	IF	CITATIONS
1	The ReWalk Powered Exoskeleton to Restore Ambulatory Function to Individuals with Thoracic-Level Motor-Complete Spinal Cord Injury. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2012, 91, 911-921.	1.4	699
2	Safety and tolerance of the ReWalk [®] exoskeleton suit for ambulation by people with complete spinal cord injury: A pilot study. <i>Journal of Spinal Cord Medicine</i> , 2012, 35, 96-101.	1.4	409
3	Unilateral upper-limb loss: Satisfaction and prosthetic-device use in veterans and servicemembers from Vietnam and OIF/OEF conflicts. <i>Journal of Rehabilitation Research and Development</i> , 2010, 47, 299.	1.6	177
4	Amputation rehabilitation and prosthetic restoration. From surgery to community reintegration. <i>Disability and Rehabilitation</i> , 2004, 26, 831-836.	1.8	143
5	Differentiating ability in users of the ReWalk [®] TM powered exoskeleton: An analysis of walking kinematics. , 2013, 2013, 6650469.		143
6	Powered Exoskeletons for Walking Assistance in Persons with Central Nervous System Injuries: A Narrative Review. <i>PM and R</i> , 2017, 9, 46-62.	1.6	124
7	Common patterns of clinical motor dysfunction. <i>Muscle and Nerve</i> , 1997, 20, 21-35.	2.2	118
8	Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. <i>Toxicon</i> , 2013, 67, 115-128.	1.6	114
9	The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 554-556.	2.3	112
10	Rehabilitation After Amputation. <i>Journal of the American Podiatric Medical Association</i> , 2001, 91, 13-22.	0.3	103
11	Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2003, 14, 855-883.	1.3	101
12	COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician's perspective. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 515-524.	2.2	87
13	Efficacy and safety of abobotulinumtoxinA in spastic lower limb. <i>Neurology</i> , 2017, 89, 2245-2253.	1.1	79
14	Temporal-Spatial Feature of Gait after Traumatic Brain Injury. <i>Journal of Head Trauma Rehabilitation</i> , 1999, 14, 105-115.	1.7	66
15	Gait analysis: clinical facts. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2016, 52, 560-74.	2.2	60
16	Rehabilitation in limb deficiency. 4. Limb amputation. <i>Archives of Physical Medicine and Rehabilitation</i> , 1996, 77, S18-S28.	0.9	59
17	Robotic-Assisted Gait Training and Restoration. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2012, 91, S217-S231.	1.4	59
18	Influence of Botulinum Toxin Type A Treatment of Elbow Flexor Spasticity on Hemiparetic Gait. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2008, 87, 305-311.	1.4	53

#	ARTICLE	IF	CITATIONS
19	The Effect of an Ankle-Foot Orthosis on Temporal Spatial Parameters and Asymmetry of Gait in Hemiparetic Patients. <i>PM and R</i> , 2009, 1, 1014-1018.	1.6	53
20	Gait Analysis in Lower-Limb Amputation and Prosthetic Rehabilitation. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2014, 25, 153-167.	1.3	48
21	A Comparison of Locomotor Therapy Interventions: Partial-Body Weight-Supported Treadmill, Lokomat, and G&EO Training in People With Traumatic Brain Injury. <i>PM and R</i> , 2017, 9, 839-846.	1.6	48
22	Effects of Botulinum Toxin-A on Gait Velocity, Step Length, and Base of Support of Patients with Dynamic Equinovarus Foot. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2006, 85, 600-606.	1.4	46
23	OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. <i>PM and R</i> , 2018, 10, 693-703.	1.6	46
24	Evaluation and Management of Spastic Gait in Patients With Traumatic Brain Injury. <i>Journal of Head Trauma Rehabilitation</i> , 2004, 19, 109-118.	1.7	42
25	Robotics for Lower Limb Rehabilitation. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2019, 30, 385-397.	1.3	42
26	A Randomized Comparative Study of Manually Assisted Versus Robotic-Assisted Body Weight Supported Treadmill Training in Persons With a Traumatic Brain Injury. <i>PM and R</i> , 2013, 5, 280-290.	1.6	40
27	A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018, 54, 605-617.	2.2	38
28	Advanced Robotic Therapy Integrated Centers (ARTIC): an international collaboration facilitating the application of rehabilitation technologies. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2018, 15, 30.	4.6	37
29	Instrumented Assessment of Muscle Overactivity and Spasticity with Dynamic Polyelectromyographic and Motion Analysis for Treatment Planning. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2004, 83, S19-S29.	1.4	35
30	Patient Registry of Outcomes in Spasticity Care. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2012, 91, 729-746.	1.4	35
31	OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review. <i>BMC Neurology</i> , 2013, 13, 118.	1.8	35
32	OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach. <i>PM and R</i> , 2017, 9, 960-968.	1.6	33
33	OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. <i>PM and R</i> , 2017, 9, 136-148.	1.6	24
34	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. <i>Toxicon</i> , 2009, 54, 634-638.	1.6	21
35	Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity. <i>Frontiers in Neurology</i> , 2020, 11, 388.	2.4	19
36	Instrumented Gait Analysis. <i>JBSJ Reviews</i> , 2016, 4, .	2.0	18

#	ARTICLE	IF	CITATIONS
37	Getting the Best Out of Advanced Rehabilitation Technology for the Lower Limbs: Minding Motor Learning Principles. <i>PM and R</i> , 2018, 10, S165-S173.	1.6	18
38	Temporospatial Parameters of Gait After Obturator Neurolysis in Patients with Spasticity. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2003, 82, 832-836.	1.4	16
39	Common patterns of clinical motor dysfunction. <i>Muscle and Nerve</i> , 1997, 20, 21-35.	2.2	16
40	Hemiparetic gait and changes in functional performance due to OnabotulinumtoxinA injection to lower limb muscles. <i>Toxicon</i> , 2015, 107, 109-113.	1.6	14
41	Pathophysiology of Gait Disturbance in Neurologic Disorders and Clinical Presentations. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2013, 24, 233-246.	1.3	13
42	Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. <i>Frontiers in Neurology</i> , 2020, 11, 576117.	2.4	13
43	Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician and Patient Reported Satisfaction: Long Term Observational Results from the ASPIRE Study. <i>PM and R</i> , 2020, 12, 1120-1133.	1.6	13
44	Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 360-368.	1.4	11
45	Assessment of Muscle Overactivity and Spasticity with Dynamic Polyelectromyography and Motion Analysis. <i>The Open Rehabilitation Journal</i> , 2010, 3, 143-148.	0.8	10
46	Rehabilitation Technologies Application in Stroke and Traumatic Brain Injury Patients. <i>Biosystems and Biorobotics</i> , 2016, , 29-64.	0.3	9
47	Prosthetic Feet and Ankle Mechanisms. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 1991, 2, 299-309.	1.3	8
48	Clinical Application of Robotics and Technology in the Restoration of Walking. , 2016, , 223-248.		8
49	Patient Registry of Spasticity Care World. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2017, 96, 881-888.	1.4	8
50	Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. <i>Journal of Rehabilitation Medicine</i> , 2017, 49, 659-666.	1.1	8
51	Fitting an Older Patient With Medical Comorbidities With a Lower Limb Prosthesis. <i>PM and R</i> , 2012, 4, 59-64.	1.6	6
52	Gait Analysis. , 2011, , 99-116.		6
53	A Comparison of the Armeo to Tabletop Assisted Therapy Exercises as Supplemental Interventions in Acute Stroke Rehabilitation: A Randomized Single Blind Study. <i>PM and R</i> , 2021, 13, 30-37.	1.6	5
54	Comment on "Assessing Effectiveness and Costs in Robot-Mediated Lower Limbs Rehabilitation: A Meta-Analysis and State of the Art". <i>Journal of Healthcare Engineering</i> , 2018, 2018, 1-3.	1.9	4

#	ARTICLE	IF	CITATIONS
55	High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study. <i>Toxicon</i> : X, 2020, 7, 100040.	2.9	4
56	Change Is Our Challenge and Our Opportunity. <i>PM and R</i> , 2014, 6, 1-3.	1.6	3
57	The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury. <i>PM and R</i> , 2021, 13, 488-495.	1.6	3
58	78. Spatiotemporal changes in gait performance due to onabotulinumtoxinA injection to lower limb muscles in patients with upper motor neuron syndrome. <i>Toxicon</i> , 2015, 93, S24-S25.	1.6	2
59	Future Trends and Research in Orthoses. , 2019, , 448-450.e1.		2
60	Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. <i>PM and R</i> , 2020, 12, 853-860.	1.6	2
61	Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. <i>PM and R</i> , 2021, 13, 1079-1093.	1.6	2
62	AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol. <i>Advances in Therapy</i> , 2021, 38, 5623-5633.	2.9	2
63	Clinical Experience and Recent Advances in the Management of Gait Disorders with Botulinum Neurotoxin. , 2009, , 192-203.		1
64	A Randomized Comparison of the Biomechanical Effect of Two Commercially Available Rocker Bottom Shoes to a Conventional Athletic Shoe During Walking in Healthy Individuals. <i>Journal of Foot and Ankle Surgery</i> , 2016, 55, 772-776.	1.0	1
65	Real-World Adherence to OnabotulinumtoxinA Treatment for Spasticity: Insights From the ASPIRE Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 2172-2184.e6.	0.9	1
66	Innovations Influencing Physical Medicine and Rehabilitation. <i>PM and R</i> , 2018, 10, S129-S130.	1.6	0
67	Impact of Vaccination in the Rate of COVID-19 Staff Infection in an Acute Inpatient. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, Publish Ahead of Print, 1031-1032.	1.4	0